Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Some users experience side-effects such as nausea, diarrhoea and fatigue. Other clinical studies have found that some patients taking weight-loss drugs lose muscle at far faster rates than those ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

It revealed that sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year, from 9.6 billion kroner (£1.1 ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Vials of Wegovy at a Novo Nordisk production line in Hillerod, Denmark. The company argues government subsidies for its weight-loss drugs will ... Novo Nordisk last week reported a 29 per cent ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and Wegovy develop ... on eye disease in type 2 diabetes patients, it's ...

In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two issues in the anti-obesity space.